Abbott, BMS Suffer Blows On Antiretrovirals Kaletra and Reyataz As Indian Patent Office Rejects Patent Claims
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - India's Deputy Controller of Patents and Designs from the Mumbai branch of the Indian Patent Office rejected Dec. 30 Abbott's patent request for its popular second-generation antiretroviral Kaletra (lopinavir/ritonavir). Abbott had applied for a patent of a heat stable formulation of Kaletra nearly three years ago